CapyFin

Calendar Reports Pricing

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Outlook Therapeutics Fiscal Q4 2018 Earnings Report | CapyFin

Outlook Therapeutics

OTLK · NASDAQ🇺🇸

Overview Earnings

Dividends Seasonality Metrics

Q2 2026 in 2mo Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 +1.63%Q4 2024 +9.41%Q3 2024 -0.90%Q2 2024 -0.95%Q1 2024 +21.25%Q4 2023 +4.21%Q3 2023 -3.13%Q2 2023 +3.48%Q1 2023 -3.33%Q4 2022 +6.93%Q3 2022 -3.36%Q2 2022 +7.38%Q1 2022 +3.70%Q4 2021 -4.17%Q3 2021 -14.62%Q2 2021 +15.98%Q1 2021 -0.40%Q4 2020 +1.31%Q3 2020 +5.22%Q2 2020 +1.87%Q1 2020 0.00%Q4 2019 -1.71%Q3 2019 -4.21%Q2 2019 +48.54%Q1 2019 +28.16%Q4 2018 +24.49%Q3 2018 +1.19%Q2 2018 +2.72%Q1 2018 +4.35%Q4 2017 0.00%Q3 2017 +0.51%Q2 2017 -8.65%Q1 2017 +10.62%Q2 2016 +28.63%Q4 2016 +28.63%Q3 2016 -3.87%Q1 2016 Q4 2015 Q3 2015 Q2 2015 Q1 2015

Dec 18, 2018

•

Sep 30, 2018

Outlook Therapeutics Q4 2018 Earnings Report

Previous year: $2.9M

Previous year: -$6.2

Cash and Equivalents

Previous year: $3.19M

Previous year: $55.9K

Previous year: $20.7M

Outlook Therapeutics

Unlock previous datapoints

Outlook Therapeutics

Unlock previous datapoints

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View Outlook Therapeutics